ASP Isotopes (NASDAQ:ASPI) Sees Large Volume Increase - Here's What Happened

Shares of ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report) saw unusually-high trading volume on Friday . Approximately 2,090,131 shares traded hands during mid-day trading, a decline of 24% from the previous session's volume of 2,744,417 shares.The stock last traded at $10.32 and had previously closed at $9.65.

Wall Street Analyst Weigh In

Separately, Canaccord Genuity Group raised their price objective on ASP Isotopes from $8.50 to $11.00 and gave the company a "buy" rating in a report on Wednesday, May 21st.

ASP Isotopes Stock Performance

The firm has a market cap of $879.90 million, a price-to-earnings ratio of -17.20 and a beta of 3.35. The stock's 50 day moving average is $7.77 and its 200 day moving average is $6.04. The company has a current ratio of 7.21, a quick ratio of 7.17 and a debt-to-equity ratio of 0.80.

Institutional Trading of ASP Isotopes

Several large investors have recently made changes to their positions in ASPI. BNP Paribas Financial Markets bought a new position in ASP Isotopes in the 4th quarter valued at approximately $34,000. SBI Securities Co. Ltd. lifted its stake in ASP Isotopes by 84.8% in the 1st quarter. SBI Securities Co. Ltd. now owns 9,370 shares of the company's stock valued at $44,000 after purchasing an additional 4,299 shares during the last quarter. Avantax Advisory Services Inc. bought a new position in ASP Isotopes in the 4th quarter valued at approximately $45,000. Russell Investments Group Ltd. lifted its stake in ASP Isotopes by 56.3% in the 4th quarter. Russell Investments Group Ltd. now owns 10,221 shares of the company's stock valued at $46,000 after purchasing an additional 3,682 shares during the last quarter. Finally, Covestor Ltd bought a new position in ASP Isotopes in the 4th quarter valued at approximately $54,000. Institutional investors and hedge funds own 16.80% of the company's stock.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.